Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX

Click on an RSS button(s) below and copy the URL into your RSS Reader to receive a feed of updated information from this site.

Not familiar with RSS?  RSS is an XML-based (eXtensible Markup Language) format for content distribution that you view with an RSS Reader.  There are a wide range of RSS Readers available - Click here for a list of some of the most popular.

  Press releases & statements (All)
    Type
    Statement
    Press release
    Topic
    Corporate and finance
    Global health
    Partnerships
    Science & technology
    Research area
    COVID-19
    Ebola
    Malaria
    RSV
    Seasonal influenza
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.